Bosentan 125 MG Oral Tablet — RxCUI 656659
RxNorm drug concept · Semantic clinical drug
RxCUI 656659
Semantic clinical drug · SCD
● Current RxNorm concept 11 FDA products
31 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI656659
Official nameBosentan 125 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbosentan (as bosentan hydrochloride) 125 MG Oral Tablet
FDA products mapped11
Package NDCs mapped31
Reported Medicaid activity (SDUD)814 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Bosentan: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Pulmonary arterial hypertension, or PAH, means the blood pressure inside the arteries in your lungs is dangerously high. That forces your heart to work much harder than it should....
- What exactly is bosentan treating — what's wrong with my lungs?
- Please don't skip them — this is one of the most important parts of being on bosentan. The drug can raise liver enzyme levels, which is a sign of stress on your liver, and this can...
- Why do I need a blood test every single month? Can I skip one if I feel fine?
🕸️ Concept Web — How Bosentan 125 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Bosentan 125 MG Oral Tablet
RxCUI 656659 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Bosentan
75207IN
-
Bosentan
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Tracleer
323502BN
-
Tracleer
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Bosentan Oral Tablet
378980SCDF -
Bosentan Oral Product
1163076SCDG -
Bosentan Pill
1163077SCDG -
Bosentan Oral Tablet [Tracleer]
367715SBDF -
Tracleer Oral Product
1178626SBDG -
Tracleer Pill
1178627SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Bosentan Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Bosentan 125 MG
351035SCDC -
Bosentan 125 MG Oral Tablet [Tracleer]
656660SBD -
Bosentan 125 MG [Tracleer]
575816SBDC
-
Bosentan 125 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Bosentan 125 MG
SCDC · 351035 -
Bosentan Oral Tablet
SCDF · 378980 -
Bosentan Oral Product
SCDG · 1163076 -
Bosentan Pill
SCDG · 1163077
Brand-Name Concepts
-
Bosentan 125 MG Oral Tablet [Tracleer]
SBD · 656660 -
Bosentan 125 MG [Tracleer]
SBDC · 575816 -
Bosentan Oral Tablet [Tracleer]
SBDF · 367715 -
Tracleer Oral Product
SBDG · 1178626 -
Tracleer Pill
SBDG · 1178627 -
Tracleer
BN · 323502
📦 FDA Products & Package NDCs
11 products · 31 package NDCs
31 package NDCs map to RxCUI 656659 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00591-2511-60 | 60 TABLET, FILM COATED in 1 BOTTLE (0591-2511-60) | bosentan | Actavis Pharma, Inc. | 2019-06-19 |
| 00591-2512-60 | 60 TABLET, FILM COATED in 1 BOTTLE (0591-2512-60) | bosentan | Actavis Pharma, Inc. | 2019-06-19 |
| 47335-0038-64 | 10 BLISTER PACK in 1 CARTON (47335-038-64) / 3 TABLET, FILM... | Bosentan | Sun Pharmaceutical Industries, Inc. | 2019-04-26 |
| 47335-0038-86 | 60 TABLET, FILM COATED in 1 BOTTLE (47335-038-86) | Bosentan | Sun Pharmaceutical Industries, Inc. | 2019-04-26 |
| 47335-0039-64 | 10 BLISTER PACK in 1 CARTON (47335-039-64) / 3 TABLET, FILM... | Bosentan | Sun Pharmaceutical Industries, Inc. | 2019-04-26 |
| 47335-0039-86 | 60 TABLET, FILM COATED in 1 BOTTLE (47335-039-86) | Bosentan | Sun Pharmaceutical Industries, Inc. | 2019-04-26 |
| 66215-0101-03 | 10 BLISTER PACK in 1 CARTON (66215-101-03) / 3 TABLET, FILM... | Tracleer | Actelion Pharmaceuticals US, Inc. | 2012-10-02 |
| 66215-0101-06 | 1 BOTTLE, PLASTIC in 1 CARTON (66215-101-06) / 60 TABLET, F... | Tracleer | Actelion Pharmaceuticals US, Inc. | 2001-11-20 |
| 66215-0102-03 | 10 BLISTER PACK in 1 CARTON (66215-102-03) / 3 TABLET, FILM... | Tracleer | Actelion Pharmaceuticals US, Inc. | 2012-10-02 |
| 66215-0102-06 | 1 BOTTLE, PLASTIC in 1 CARTON (66215-102-06) / 60 TABLET, F... | Tracleer | Actelion Pharmaceuticals US, Inc. | 2001-11-20 |
| 66215-0232-56 | 4 BLISTER PACK in 1 CARTON (66215-232-56) / 14 TABLET, FOR... | Tracleer | Actelion Pharmaceuticals US, Inc. | 2021-07-29 |
| 68382-0446-01 | 100 TABLET, COATED in 1 BOTTLE (68382-446-01) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0446-05 | 500 TABLET, COATED in 1 BOTTLE (68382-446-05) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0446-14 | 60 TABLET, COATED in 1 BOTTLE (68382-446-14) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0446-28 | 180 TABLET, COATED in 1 BOTTLE (68382-446-28) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0446-77 | 10 BLISTER PACK in 1 CARTON (68382-446-77) / 10 TABLET, COA... | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0447-01 | 100 TABLET, COATED in 1 BOTTLE (68382-447-01) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0447-05 | 500 TABLET, COATED in 1 BOTTLE (68382-447-05) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0447-14 | 60 TABLET, COATED in 1 BOTTLE (68382-447-14) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0447-28 | 180 TABLET, COATED in 1 BOTTLE (68382-447-28) | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 68382-0447-77 | 10 BLISTER PACK in 1 CARTON (68382-447-77) / 10 TABLET, COA... | Bosentan | Zydus Pharmaceuticals USA Inc. | 2019-05-01 |
| 70771-1017-01 | 100 TABLET in 1 BOTTLE (70771-1017-1) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1017-04 | 10 BLISTER PACK in 1 CARTON (70771-1017-4) / 10 TABLET in 1... | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1017-05 | 500 TABLET in 1 BOTTLE (70771-1017-5) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1017-06 | 60 TABLET in 1 BOTTLE (70771-1017-6) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1017-08 | 180 TABLET in 1 BOTTLE (70771-1017-8) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1018-01 | 100 TABLET in 1 BOTTLE (70771-1018-1) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1018-04 | 10 BLISTER PACK in 1 CARTON (70771-1018-4) / 10 TABLET in 1... | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1018-05 | 500 TABLET in 1 BOTTLE (70771-1018-5) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1018-06 | 60 TABLET in 1 BOTTLE (70771-1018-6) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
| 70771-1018-08 | 180 TABLET in 1 BOTTLE (70771-1018-8) | Bosentan | Zydus Lifesciences Limited | 2019-05-01 |
Observed labelers:
Zydus Lifesciences Limited (10) ·
Zydus Pharmaceuticals USA Inc. (10) ·
Actelion Pharmaceuticals US, Inc. (5) ·
Sun Pharmaceutical Industries, Inc. (4) ·
Actavis Pharma, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.